GSK Makes New Adult Immunization Push, Seeks Reimbursement Changes Following RSV Approvals
Executive Summary
From ACIP to Part D to data transparency, GSK has several policy asks as it prepares to launch its new RSV vaccine for older adults. The Pink Sheet spoke with GSK’s vaccine policy lead about the firm’s new data platform and the worrisome US vaccination trends following the Covid pandemic.
You may also be interested in...
AstraZeneca’s RSV Antibody May Need More Data Due To Impact Of Maternal Vaccines
Maternal vaccines may cause first RSV infections to occur when infants are older, requiring increased study of disease patterns and additional dosing data on AstraZeneca/Sanofi’s nirsevimab in older babies.
Pfizer, GSK US RSV Vaccine Uptake Likely Hurt By ACIP’s Weaker Recommendation
Price tag, inadequate trial designs, safety and questions about possibility of boosters were among the reasons CDC advisors voted that adults 60 and over ‘may’ receive an RSV vaccine. A stronger ‘should’ receive RSV vaccine had seemed possible for the over 65 group earlier this year.
GSK’s Walmsley On US v. EU COVID-Flu Combos, RSV Branding, And Investing In Infectious Disease
COVID vaccine makers already licensed in the US will have a leg up on in the combination respiratory vaccine space since aspiring new entrants like GSK will have to do efficacy work to get FDA approval. CEO Walmsley offers insight into the company’s vaccine strategy.